Clinical Trials Logo

Clinical Trial Summary

This is a feasibility study and the goal of this project is to evaluate whether ACC glutamine, quantified as a CSF-corrected absolute concentration percent change from baseline, is associated with clinical remission, Montgomery Asberg Depression Rating Scale (MADRS) total score of =9, to the anti-glutamatergic antidepressant ketamine. As MRS is expensive, we also aim to study a correlation between peripheral glutamate and central glutamate level.


Clinical Trial Description

Aims:

This feasibility study aims to better understand the neurobiology of major depression and how ketamine may therapeutically impact brain function. This research may provide important insights into the mechanism of ketamine response, thus, potentially increasing the likelihood of successful treatment interventions and decrease the number of ineffective treatments and/or risk for serious side effects.

SPECIFIC AIMS:

Primary aim: Evaluate change in central glutamate (i.e. MR spectroscopic CSF corrected glutamate in ACC) and peripheral glutamate (i.e. high-performance liquid chromatography [HPLC] measured glutamate) after a single 40-minute infusion of i.v. racemic ketamine, and change in symptoms of depression measured using MADRS scale in patients with treatment-resistant major depression (baseline to 24 hours) (n=10). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03573349
Study type Interventional
Source Mayo Clinic
Contact Jose Rico
Phone 507-255-9352
Email rico.jose@mayo.edu
Status Not yet recruiting
Phase Early Phase 1
Start date August 2018
Completion date December 2019

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Suspended NCT02940769 - Neurobiological Effects of Light on MDD Early Phase 1
Recruiting NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT03113890 - McLean and Genomind Prospective Study N/A
Recruiting NCT03449979 - Single Session of tACS in a Depressive Episode N/A
Not yet recruiting NCT03672175 - A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder Phase 3
Not yet recruiting NCT03068247 - Neurobiology of Treatment Responses in MDD Phase 3
Recruiting NCT02939560 - TMS for Adults With Autism and Depression N/A
Recruiting NCT02674529 - Study of Neural Responses Induced by Antidepressant Effects Phase 2/Phase 3
Active, not recruiting NCT02934035 - Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder N/A
Completed NCT02855580 - Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
Not yet recruiting NCT02766920 - Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone N/A
Completed NCT02309060 - Storytelling Video Intervention for Depressed Primary Care Patients - Open Trial N/A
Recruiting NCT02530164 - Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression N/A
Recruiting NCT02624102 - Efficacy of Trial-Based Cognitive Therapy and Behavioral Activation in Treatment of Depression Phase 3
Recruiting NCT02922556 - Piloting a Novel, Mobile Cognitive Training Tool for Patients With Major Depressive Disorder (MDD) N/A
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study N/A
Not yet recruiting NCT02502604 - Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder N/A
Withdrawn NCT01613820 - Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder N/A